Stephanie Lodise, Ph.D.

Subscribe to all posts by Stephanie Lodise, Ph.D.

Podcast: Navigating the Fine Line Between Obviousness and Obviousness-Type Double Patenting

Photo of Stephanie Lodise, Ph.D.Photo of Tracy Palovich, Ph.D.By Stephanie Lodise, Ph.D. and Tracy Palovich, Ph.D. on Posted in Patents, Podcast
Partner Stephanie Lodise, Ph.D., and Patent Agent Tracy Palovich, Ph.D., break down the differences between obviousness rejections and obviousness-type double patenting rejections. They then provide important prosecution strategies how to respond to each type of rejection so as to maximize patent protection Questions & Comments: slodise@bakerlaw.com Listen to the Episode Subscribe to BakerHosts Apple Podcast | Google … Continue Reading

Be Sure to Ask Your Scientists the Right Questions or Risk Losing Patent Protection

Photo of Fabian KoenigbauerPhoto of Stephanie Lodise, Ph.D.By Fabian Koenigbauer and Stephanie Lodise, Ph.D. on Posted in Patent
Welcome to the IP Intelligence Blog. We have merged the Copyright, Content, and Platforms blog into the IP Intelligence Blog to provide a single source for IP updates. We hope you enjoy our thought provoking posts on Intellectual Property related topics. Under the first-to-file patent system in place in the U.S. and globally, a publication … Continue Reading

The Federal Circuit Reverses a Hindsight Reconstruction of An Important Pharmaceutical Invention

Photo of Stephanie Lodise, Ph.D.Photo of Laura GordonBy Allen Sokal, Stephanie Lodise, Ph.D. and Laura Gordon on Posted in Patent
In Millennium Pharmaceuticals v. Sandoz,[1] the Federal Circuit reversed the district court’s holding of obviousness of certain claims of Millennium-owned U.S. Patent No. 6,713,446 (the ‘446 patent), finding that the district court improperly applied the lead compound analysis and the inherency doctrine and clearly erred by rejecting objective indicia of non-obviousness. The disputed claims of … Continue Reading

Patent Trial and Appeal Board Denies Inter Partes Review of Patent Claiming the Deuterated Form of a Known Compound

Photo of Laura GordonPhoto of Stephanie Lodise, Ph.D.By Laura Gordon and Stephanie Lodise, Ph.D. on Posted in Uncategorized
In Neptune Generics, LLC v. Auspex Pharmaceuticals, Inc., IPR2015-01313, Paper No. 25 (PTAB Dec. 9, 2015) (“Neptune”), the Patent Trial and Appeal Board (“the Board”) issued an opinion denying institution of inter partes review of U.S. Patent No. 7,456,317 B2 (“the ’317 patent”). The ’317 patent claims an analog of venlafaxine (Effexor®) in which nine … Continue Reading

Momenta Pharma., Inc. v. Teva Pharma. USA Inc.

Photo of Stephanie Lodise, Ph.D.By Stephanie Lodise, Ph.D. on Posted in Uncategorized
In Momenta Pharma., Inc. v. Teva Pharma. USA Inc., Nos. 2014-1274, -1277, -1276, and -1278 (Fed. Cir. Nov. 10, 2015) (“Momenta II”), the Federal Circuit found that, pursuant to 35 U.S.C. § 271(g), “made” is limited to steps directly related to manufacturing products and excludes isolated quality control steps. The court also revisited its prior … Continue Reading
LexBlog